Suicidality and Antidepressant Drugs
Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of NORPRAMIN or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. NORPRAMIN is not approved for use in pediatric patients. (See WARNINGS: Clinical Worsening and Suicide Risk, PRECAUTIONS: Information for Patients, and PRECAUTIONS: Pediatric Use.)
|
| |
NORPRAMIN SUMMARY
NORPRAMIN® (desipramine hydrochloride USP) is an antidepressant drug of the tricyclic type.
NORPRAMIN (desipramine hydrochloride) is indicated for the treatment of depression.
|
|
NEWS HIGHLIGHTSMedia Articles Related to Norpramin (Desipramine)
Brain Inflammation Tied to Depression, Suicidal Thoughts
Source: Medscape Pathology & Lab Medicine Headlines [2017.09.29]
Animal and postmortem studies point to a link between neuroinflammation and depression and suicidality. This study used PET scans to corroborate these findings in living human beings.
Medscape Medical News
Sleep Deprivation a Rapid, Effective Depression Treatment
Source: Medscape Psychiatry & Mental Health Headlines [2017.09.27]
Sleep deprivation therapy may offer a rapid and effective treatment for depression, but results are short-lived. The question now is how to sustain benefit.
Medscape Medical News
Postpartum Depression Likely to Recur With Future Pregnancies
Source: MedicineNet Depression Specialty [2017.09.27]
Title: Postpartum Depression Likely to Recur With Future Pregnancies
Category: Health News
Created: 9/26/2017 12:00:00 AM
Last Editorial Review: 9/27/2017 12:00:00 AM
Cancer Patients May Have Undiagnosed Depression
Source: MedicineNet Depression Specialty [2017.09.25]
Title: Cancer Patients May Have Undiagnosed Depression
Category: Health News
Created: 9/25/2017 12:00:00 AM
Last Editorial Review: 9/25/2017 12:00:00 AM
Asthma Drug Tied to Nightmares, Depression
Source: MedicineNet Allergy Specialty [2017.09.22]
Title: Asthma Drug Tied to Nightmares, Depression
Category: Health News
Created: 9/21/2017 12:00:00 AM
Last Editorial Review: 9/22/2017 12:00:00 AM
Published Studies Related to Norpramin (Desipramine)
Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual
orexin receptor antagonist, and desipramine. [2014]
Almorexant is a dual orexin receptor antagonist (DORA) with sleep-enabling
effects in humans. Insomnia is often associated with mental health problems,
including depression... The lack
of a relevant interaction with antidepressants, if confirmed for other DORAs,
would be a key feature for a safer class of hypnotics.
Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial. [2010.09]
OBJECTIVE: To estimate the efficacy of common treatments for vulvodynia: topical lidocaine monotherapy, oral desipramine monotherapy, and lidocaine-desipramine combined therapy... CONCLUSION: Oral desipramine and topical lidocaine, as monotherapy or in combination, failed to reduce vulvodynia pain more than placebo. Placebo or placebo-independent effects are behind the substantial pain improvement seen in all treatment allocations. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, www.clinicaltrials.gov, NCT00276068. LEVEL OF EVIDENCE: I.
Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled
trial. [2010]
combined therapy... CONCLUSION: Oral desipramine and topical lidocaine, as monotherapy or in
A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. [2006.02]
CONCLUSION: The small number of women in this study most likely contributed to the lack of observed differences in efficacy observed during the 6 weeks of treatment. Randomized, placebo-controlled trials of adequate power seeking to determine efficacy of antidepressants in the United States for the treatment of women with breast cancer and comorbid depression remain of paramount importance.
Desipramine treatment of cocaine-dependent patients with depression: a placebo-controlled trial. [2005.11.01]
CONCLUSIONS: Desipramine was an effective treatment for depression among cocaine-dependent patients. Improvement in mood was associated with improvement in cocaine abuse, but a direct effect of medication on cocaine outcome was not clearly established and rates of sustained abstinence were low. Future research should examine newer antidepressant medications with more benign side effect profiles and combinations of behavioral and pharmacological treatments to maximize effects on cocaine use.
Clinical Trials Related to Norpramin (Desipramine)
Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant [Active, not recruiting]
This pilot clinical trial studies how well desipramine hydrochloride and filgrastim works
for stem cell mobilization in patients with multiple myeloma undergoing stem cell
transplant. Giving colony-stimulating factors, such as filgrastim, and other drugs, such as
desipramine hydrochloride, helps stem cells move from the patient's bone marrow to the blood
so they can be collected and stored.
To Evaluate the Effect of Mirabegron (YM178) on Blood Levels of Desipramine When They Are Taken Together [Completed]
The study aims to evaluate if blood levels of desipramine change whilst being dosed at the
same time with daily mirabegron.
Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome [Completed]
Rett syndrome is a neurodevelopmental disorder characterized by cognitive impairment,
communication dysfunction, stereotypic movement disorder, and growth failure. Rett syndrome
is caused by mutations in the Methyl CpG-Binding Protein-2 (MECP2) gene and has no
treatment.
A mouse experimental model of Rett syndrome created by genetic invalidation of the MECP2
gene is available. It had been then observed that adult MECP2-deficient mice show
respiratory alterations and found that endogenous noradrenaline helps to maintain a normal
respiratory rhythm. Desipramine, a selective inhibitor of norepinephrine reuptake, seems to
be efficient to reduce the respiratory alteration occuring in MECP2-deficient mice (Insem
patent 2005, Villard and Roux 2006).
The aim of the study is to evaluate these obtained results in MECP2-deficient mice on
patients with Rett syndrome.
To Demonstrate the Relative Bioequivalency of Cord's 100 mg Desipramine HCL Tablets To Merrell Dow's 100 mg Norpramin Tablets [Completed]
To demonstrate the relative bioequivalency of Cord's 100 mg Desipramine HCl tablets to
Merrell Dow's 100 mg Norpramin tablets.
To Demonstrate the Relative Bioequivalency of Comparing Single 100 mg Doses Of Cord's 50 mg Desipramine HCL Tablets To Merrell Dow's 50 mg Norpramin Tablets [Completed]
To demonstrate the relative bioequivalency of comparing single 100 mg doses Of Cord's 50 mg
Desipramine Hcl tablets to Merrell Dow's 50 mg Norpramin tablets.
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 1 ratings/reviews, Norpramin has an overall score of 6. The effectiveness score is 6 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
| | Norpramin review by 44 year old female patient | | | Rating |
| Overall rating: | |   |
| Effectiveness: | | Moderately Effective |
| Side effects: | | Mild Side Effects | | |
Treatment Info |
| Condition / reason: | | migraine |
| Dosage & duration: | | 50 mg taken 1 time per day for the period of 3 years |
| Other conditions: | | migraines |
| Other drugs taken: | | Topamax | | |
Reported Results |
| Benefits: | | no a.m. headaches |
| Side effects: | | mild drowsiness |
| Comments: | | took away morning headaches until I was able to get a better handle on my migraines. |
|
|
|
Page last updated: 2017-09-29
|
